In its first major deal, Danish biotech Symphogen AS agreed to a $330 million collaboration with Genentech Inc. to discover and develop antibody therapeutics against three undisclosed infectious disease targets.(BioWorld Today) Read More
No AbstractBelgian firm UCB SA licensed Japanese co-promotion rights to two drugs, Keppra and Cimzia, to Otsuka Pharmaceuticals Co. Ltd. in a deal that could be worth as much as €113 million (US$174 million) to UCB. Read More
